Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update

MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.

Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update

MoonLake Immunotherapeutics (NASDAQ:MLTX) is placed eighth on our list of most promising stocks.

TheFly reported on February 26 that Goldman Sachs increased its price target on MLTX to $11 from $10 and maintained a Sell rating. The update followed the company’s fourth-quarter and full-year results, with cash expected to fund operations into the second half of 2027 under its Hercules Capital facility. Although MLTX provided pipeline updates, the firm continues to question the likelihood of regulatory approval for sonelokimab.

On February 22, MoonLake Immunotherapeutics (NASDAQ:MLTX) disclosed topline findings from the Phase 2 S-OLARIS study of SLK in individuals with radiographic and non-radiographic axial spondyloarthritis (axSpA). In the trial, 81% of treated patients (n=26, mNRI) achieved an ASAS40 response at Week 12, alongside more than 80% reaching clinically important improvement based on ASDAS-CRP.

Imaging assessments, which include SPARCC MRI of the sacroiliac joints and 18F-NaF PET scans, showed reductions in inflammation and osteoblast activity. Biomarker analyses indicated rapid and sustained suppression of inflammatory pathways, and the safety results aligned with prior studies without identifying new safety concerns. The company intends to advance SLK into further clinical development, with additional updates shared during its fourth-quarter and full-year results announcement.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing novel Nanobody therapies, including sonelokimab, to treat inflammatory diseases like hidradenitis suppurativa and psoriatic arthritis, aiming to improve patient outcomes through advanced immune-targeted medicines.

While we acknowledge the potential of MLTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MLTX and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 14 Best GARP Stocks to Buy According to Analysts and 14 Best Affordable Dividend Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.